Author(s): Mathew George, Lincy Joseph , Rani Manju, Gifty Ann Thomas, Maleetha Shamsudeen, Shefali K Thomas, Vineetha.C.J
Aim: To study the adequacy of myocardial protection with cardioplegia solution in patients undergoing cardiac surgery using CKMB as biomarke. Cardioplegia is the intentional and temporary cessation of cardiac activity primarily for cardiac surgery. Acting as perfusion agent, cardioplegia solutions can alter or inhibit ischemic injury by virtue of hypothermia and asystole. CPK-MB is the most sensitive and the most specific indicator available for the diagnosis of an acute myocardial infarction during the surgery which asseses adequacy of cadioplegia. Materials and Methods: This prospective analytical study was conducted in the department of Cardiothoracic and Vascular Surgery , Pushpagiri Medical College Hospital, Thiruvalla . All patients who were willing to participate in the study were briefly explained about the study procedure. Approximately 60-65 patients will be taken into consideration. Blood sample (residual) of 3ml is required which is obtained from the laboratory and CPK-MB level is estimated 6th and 12th hourly after administration of cardioplegic solution. The patients are selected based on inclusion and exclusion criteria. The level of biomarker can be analysed by using semi auto analyzer. The results obtained from the study can be compared with the normal range of CPK MB in blood. Follow up will be conducted during the study period. Results: Out of 70 patients evaluated, 65 patients was found to have a safer CK-MB ratio level(0-5%) . Comorbidities were compared with CK-MB level at 6th and 12th hourly and was found that diabetic patients with HTN shows comparitively higher average CKMB value. Other than 5% of those patients having higher CK-MB level ,postoperative QOL of 95% In addition, cardioplegia solutions can be used to avoid reperfusion injury.. This review is designed to investigate the adequacy of cardioplegia solution in of patients was found to be increased (p value<0.05).